Explore our list of non-proprietary assays
Please contact us with any questions or if your compound is not on this list.
Compound(s) | Species Matrix | Validated Range | Anticoagulant (s) |
---|---|---|---|
Abacavir | Human Plasma | 10.0–2,000 ng/mL | K2EDTA |
Abiraterone | Human Plasma | 0.200–200 ng/mL | K2EDTA |
Acetaminophen | Human Dried Blood Spot | 50.0–30,000 ng/mL | Sodium Heparin |
Acetaminophen | Human Plasma | 50.0–30,000 ng/mL | Sodium Heparin |
Acetaminophen | Human Urine | 1.00–250 µg/mL | NA |
Albuterol | Human Plasma | 1.00–1,000 pg/mL | K2EDTA |
Amprenavir | Human Plasma | 10.0–10,000 ng/mL | K2EDTA /K3EDTA |
Apixiban | Human Plasma | 5.00–1,000 ng/mL | K2EDTA |
Aripiprazole | Human Plasma | Human Plasma | K3EDTA |
Atazanavir | Human Plasma | 1.00–1,000 ng/mL | K3EDTA |
Atazanavir | Human Plasma | 10.0–5,000 ng/mL | K2/K3EDTA |
Atazanavir | Human Plasma | 25.0–5,000 ng/mL | K2EDTA |
Atazanavir | Human Plasma | 10.0–10,000 ng/mL | K2EDTA |
ATRIPLA™ (Tenofovir, Emtricitabine, Efavirenz) | Human Plasma | 5.00–5,000 ng/mL | K2EDTA |
Bortezomib | Human Plasma | 0.500–500 ng/mL | Sodium Heparin |
Budesonide | Human Plasma | 3.00–300 pg/mL | EDTA |
Budesonide | Human Plasma | 10.0–5,000 pg/mL | K2EDTA |
Buprenorphine | Human Plasma | 25.0–10,000 pg/mL | K2EDTA |
Buprenorphine | Human Plasma | 0.0500–20.0 ng/mL | K3EDTA |
Bupropion | Human Plasma | 1.00–1,000 ng/mL | K2EDTA |
Bupropion | Human Plasma | 1.00–1,000 ng/mL | K2EDTA |
Bupropion, Hydroxybupropion | Human Plasma | 0.0500–2,500 ng/mL | K2EDTA |
Bupropion/ Hydroxybupropion/ Erythrohydrobupropion / Threohydrobupropion | Human Plasma | 1.00–1,000 ng/mL | Sodium Heparin |
Capecitabine | Human Plasma | 10.0–1,000 ng/mL | K2EDTA |
Capsaicin | Human Plasma | 0.0500–50.0 ng/mL | K2EDTA |
Clarithromycin | Human Plasma | Human Plasma | MSN |
Clindamycin | Human Plasma | 50–50,000 ng/mL | K2EDTA |
Cortisol | Human Urine | Human Urine | IND |
Cortisol / 6beta-hydroxycortisol | Human Urine | 1.00–400 ng/mL for Cortisol 2.50–1,000 ng/mL for 6beta-hydroxycortisol | NA |
Cyclophosphamide | Human Plasma | 20.0–10,000 ng/mL | K2EDTA |
Cyclosporin A | Human Whole Blood | 5.00–2,000 ng/mL | K2EDTA /K3EDTA |
Cyclosrporine | Human Whole Blood | 2.00–2,000 ng/mL | K2EDTA |
Darunavir | Human Plasma | 20.0–4,000 ng/mL | K2EDTA |
Darunavir | Human Plasma | 10.0–10,000 ng/mL | K2EDTA |
Dexamethasone | Human Plasma | 0.250–250 ng/mL | K2EDTA |
Dextromethorphan | Human Plasma | 1.00–500 ng/mL | K2EDTA |
Dextromethorphan | Human Urine | 1.00–500 ng/mL | NA |
Dextromethorphan | Human Urine | 1.00–500 ng/mL | NA |
Dextrorphan | Human Urine | 50.0–25,000 ng/mL | NA |
Dextrorphan | Human Plasma | 1.00–500 ng/mL | K2EDTA |
Dextrorphan | Human Urine | 1.00–500 ng/mL | NA |
Diclofenac | Human Plasma | 0.100–100 ng/mL | NaHep |
Diclofenac | Human Plasma | 10.00–2,000 ng/mL | K2EDTA |
Digoxin | Human Plasma | 100–50,000 pg/mL | K2EDTA |
Digoxin | Human Urine | 1.00–100 ng/mL | NA |
Docetaxel | Human Plasma | 10.0–10,000 ng/mL | K2EDTA /K3EDTA |
Doxorubicin | Human Plasma | 5.00–1,000 ng/mL | K2EDTA |
Doxorubicin / Doxorubicinol | Human Plasma | 5.00–5,000 ng/mL | K2EDTA |
Doxorubicinol | Human Plasma | 2.00–400 ng/mL | K2EDTA |
Efavirenz | Human Plasma | 10.0–2,000 ng/mL | K2EDTA |
Efavirenz | Human Plasma | 5.00–5,000 ng/mL | K2EDTA |
Emtricitabine | Human Plasma | 5.00–5,000 ng/mL | K2EDTA |
Emtricitabine | Human Plasma | 5.00–3,000 ng/mL | K2EDTA |
Entecavir | Human Plasma | 0.0400–16.0 ng/mL | K2EDTA |
Erythrohydrobupropion | Human Plasma | 1.00–1,000 ng/mL | K2EDTA |
Erythrohydrobupropion | Human Plasma | 1.00–1,000 ng/mL | K2EDTA |
Esomeprazole | Human Plasma | 5.00–5,000 ng/mL | K2EDTA |
Eszopiclone | Human Plasma | 1.00–100 ng/mL | K3EDTA |
Etravirine | Human Plasma | 2.00–400 ng/mL | K2EDTA |
Everolimus | Human Whole Blood | 0.200–50.0 ng/mL | K2EDTA |
Famotidine | Human Plasma | 1.00–500 ng/mL | K3EDTA |
Famotidine | Human Plasma | 1.00–500 ng/mL | K3EDTA |
Fluconazole | Human Plasma | 100–10,000 ng/mL | K3EDTA |
Fluconazole | Human Plasma | 20.0–10,000 ng/mL | K2EDTA |
Fluoxetine | Human Plasma | 0.100–50.0 ng/mL | K2EDTA |
Fluticasone propionate | Human Plasma | 5.00–1,000 pg/mL or 5.00–500 pg/mL | K3EDTA |
Fluticasone propionate | Human Plasma | 1.00–200 pg/mL | K2EDTA |
Fluticasone propionate | Human Plasma | 3.00–300 pg/mL | K2EDTA |
Formoterol | Human Plasma | 1.00–100 pg/mL | EDTA |
Formoterol | Human Plasma | 1.00–100 pg/mL | K3EDTA |
Furosemide | Human Plasma | 10.0–10,000 ng/mL | K2EDTA |
Gemfibrozil | Human Plasma | Human Plasma | IND |
Gemfibrozil | Human Plasma | 50.0–50,000 ng/mL | K2EDTA |
Guanfacine | Human Plasma | 0.0500–5.00 ng/mL | K2EDTA |
Hydrochlorothiazide | Human Plasma | 1.00–200 ng/mL | K2EDTA |
Hydroxybupropion | Human Plasma | 1.00–1,000 ng/mL | K2EDTA |
Hydroxybupropion | Human Plasma | 1.00–1,000 ng/mL | K2EDTA |
Ibandronate | Human Plasma | 0.100–50.0 ng/mL | K2EDTA |
Ibandronate | Human Plasma | 0.200–200 ng/mL | K2EDTA |
Iohexol | Human Plasma | 1.00–500 μg/mL | K2 EDTA |
Iohexol | Human Urine | 2.00–1,000 μg/mL | NA |
Irinotecan / SN-38 | Human Plasma | 5.00–2,500 ng/mL for Irinotecan and 1.00–500 ng/mL for SN-38 | K2EDTA |
Itraconazole | Human Plasma | 1.00–1,000 ng/mL | K2EDTA |
Itraconazole / Hydroxy Itraconazole | Human Plasma | 2.00–1,000 ng/mL | K2EDTA |
Ketoconazole | Human Plasma | 50.0–5,000 ng/mL | Sodium Heparin |
Ketoconazole | Human Plasma | 50.0–5,000 ng/mL | K2EDTA |
Ketoconazole | Human Plasma | 50.0–5,000 ng/mL | K2EDTA |
Ketoconazole | Human Plasma | 20.0–10,000 ng/mL | K2EDTA |
Lamivudine | Human Plasma | 10.0–2,000 ng/mL | K2EDTA |
Lenalidomide | Human Plasma | 1.00–1,000 ng/mL | K2EDTA |
Lopinavir | Human Plasma | 5.00–5,000 ng/mL | K2EDTA /K3EDTA |
Losartan / Losartan Carboxylic Acid | Human Plasma | 1.00–1,500 ng/mL | K2EDTA |
LTE4 | Human Urine | 2.00–500 pg/mL | NA |
Maraviroc | Human Plasma | 1.00–1,000 ng/mL | K2EDTA |
Mefenamic acid | Human Plasma | 50.0–5,000 ng/mL | K3EDTA |
Memantine | Human Plasma | 0.100–100 ng/mL | K3EDTA |
Mesalamine | MeCN Ext from HuP | 2.00–2,000 ng/mL | K2EDTA |
Methadone/EDDP | Human Plasma | 0.200–400 ng/mL | K2EDTA |
Methadone/EDDP | Human Urine | 0.200–400 ng/mL | NA |
Methotrexate | Human Plasma | 1.00–500 ng/mL | NaEDTA |
Methotrexate / 7-Hydroxymethotrexate | Human Plasma | 1.00–500 ng/mL | K2EDTA |
Methotrexate / 7-Hydroxymethotrexate | Human Urine | 1,000–50,000 ng/mL / 50.0–2,500 ng/mL | NA |
Methyl-Prednisolone | Human Plasma | 1.00–1,000 ng/mL | K2EDTA |
Midazolam / 1-Hydroxymidazolam | Human Plasma | 0.200–10.0 ng/mL | EDTA/Lithium Heparin |
Midazolam / 1-Hydroxymidazolam | Human Plasma | 0.100–10.0 ng/mL | Na2EDTA |
Midazolam / 1-Hydroxymidazolam | Human Plasma | 0.200–10.0 ng/mL | K2EDTA |
Midazolam and Fexofenadine | Human Plasma | 0.100–300 ng/mL 2.00–6,000 ng/mL | K2EDTA |
Midazolam and α-Hydroxymidazolam | Human Plasma | 0.100–100 ng/mL | K2EDTA |
Moexipril | Human Plasma | 1.00–200 ng/mL | K2EDTA |
Montelukast and Montelukast 1,2-diol | Human Plasma | 5.00–1,000 ng/mL | K2EDTA |
Morphine | Human Plasma | 0.500–100 ng/mL | K2EDTA |
Morphine / Morphine-3β-D-glucuronide / Morphine-6β-D-glucuronide | Human Plasma | 0.500–50.0 ng/mL / 10.0–1,000 ng/mL / 1.00–100 ng/mL | K2EDTA |
Morphine-6-β-D-glucuronide | Human Plasma | 2.50–500 ng/mL | K2EDTA |
Moxifloxacin | Human Plasma | 25.0–5,000 ng/mL | K2EDTA |
Moxifloxacin | Human Plasma | 25.0–5,000 ng/mL | NaHep |
Moxifloxacin | Human Plasma | 25.0–5000 ng/mL | Sodium Heparin |
Mycophenolic acid | Human Plasma | 2.50–2500 ng/mL | K2EDTA |
Mycophenolic acid-β-D-Glucuronide | Human Plasma | 25.0–25,000 ng/mL | K2EDTA |
Naloxone | Human Plasma | 0.00500–2.00 ng/mL | K3EDTA |
Naltrexone / Naltrexol | Human Plasma | 0.0200–2.00 ng/mL / 0.500–50.0 ng/mL | K2EDTA |
Nelfinavir | Human Plasma | 1.00–1,000 ng/mL | K2EDTA /K3EDTA |
Nevirapine | Human Plasma | 20.0–4,000 ng/mL | K2EDTA |
Nifedipine | Human Plasma | 1.00–250 ng/mL | K2EDTA |
Nilotinib | Human Plasma | 5.00–2,000 ng/mL | K2EDTA |
Nisoldipine | Human Plasma | 50.0–10,000 pg/mL | K2EDTA |
Norbuprenorphine | Human Plasma | 50.0–20,000 pg/mL | K2EDTA |
Norbuprenorphine | Human Plasma | 0.100–40.0 ng/mL | K3EDTA |
Norethindrone/Ethinyl Estradiol | Human Plasma | 50.0–15,000 pg/mL 5.00–1,500 pg/mL | K2EDTA |
Norfluoxetine aka Seproxetine | Human Plasma | 0.100–50.0 ng/mL | K2EDTA |
Octreotide | Human Plasma | 0.0500–20.0 ng/mL | K2EDTA |
Olanzapine | Human Plasma | 0.250–100 ng/mL | K2EDTA |
Omeprazole | Human Plasma | 1.00–1,000 ng/mL | K2EDTA |
Omeprazole / 5-Hydroxy Omeprazole | Human Plasma | 10.0–1,000 ng/mL | K2EDTA /K3EDTA |
Paclitaxel | Human Plasma | 10.0–2,000 ng/mL | K3EDTA |
Pramipexole | Human Plasma | 50.0–5,000 pg/mL | K3EDTA |
Pramipexole | Human Plasma | 25.0–2,500 pg/mL | K2EDTA /K3EDTA |
Prednisone | Human Plasma | 1.00–1,000 ng/mL | K2EDTA |
Pregabalin | Human Plasma | 50.0–20,000 ng/mL | K2EDTA |
Prenisolone | Human Plasma | 1.00–1,000 ng/mL | K2EDTA |
R,S-Methadone | Human Plasma | 0.500–100 ng/mL | K3EDTA |
R,S-Methadone | Human Plasma | 5.00–1,000 ng/mL | K2EDTA /K3EDTA |
Raltegravir | Human Plasma | 1.00–1,000 ng/mL | K2EDTA |
Raltegravir | Human Plasma | 1.00–1,000 ng/mL | K2EDTA |
Raltegravir II | Human Plasma | 10.0–10,000 ng/mL | K2EDTA |
Ramelteon | Human Plasma | 0.0500–8.00 ng/mL | K2EDTA |
Ribavirin | Human Plasma | 5.00–5,000 ng/mL | K2EDTA |
Rifampin | Human Plasma | 50.0–35,000 ng/mL | K2EDTA and Sodium Fluoride/Potassium Oxalate |
Rifampin | Human Plasma | 100–10,000 ng/mL | K2EDTA |
Rifaximin | Human Plasma | 0.100–10.0 ng/mL | K2EDTA |
Rilpivirine | Human Plasma | 1.00–500 ng/mL | K2EDTA |
Riluzole | Human Dried Blood Spot | 5.00–2,000 ng/mL | K2EDTA |
Riluzole | Human Plasma | 5.00–2,000 ng/mL | K2EDTA /K3EDTA |
Risperidone / 9-Hydroxyrisperidone | Human Plasma | 0.200–100 ng/mL | K2EDTA |
Ritonavir | Human Plasma | 1.00–1,000 ng/mL | K3EDTA |
Ritonavir | Human Plasma | 5.00–5,000 ng/mL | K2EDTA /K3EDTA |
Ritonavir | Human Plasma | 10.0–5,000 ng/mL | K2EDTA /K3EDTA |
Rosiglitazone | Human Plasma | 1.00–1,000 ng/mL | K2EDTA /K3EDTA |
Rosuvastatin | Human Plasma | 0.100–100 ng/mL | K2EDTA |
Rosuvastatin / Desmethyl Rosuvastatin / Rosuvastatin Lactone | Human Plasma | 0.0200–20.0 ng/mL for Rosuvastatin 0.100–10.0 ng/mL for Desmethyl Rosuvastatin 0.0500–10.0 ng/mL for Rosuvastatin Lactone | K2EDTA |
R-Warfarin | Human Plasma | 10.0–2,500 ng/mL | K2EDTA |
Salmeterol | Human Plasma | 2.50–500 pg/mL | K3EDTA |
Salmeterol | Human Plasma | 1.00–100 pg/mL | K2EDTA |
Salmeterol | Human Plasma | 1.00–200 pg/mL | K2EDTA |
Saquinavir | Human Plasma | 2.00–400 ng/mL | K2EDTA |
Scopolamine | Human Plasma | 0.00200–2.00 ng/mL | K2EDTA |
Sertraline / N-desmethylsertraline | Human Plasma | 0.250–100 ng/mL for Sertraline 0.500–100 ng/mL for N-desmethylsertraline | Sodium Heparin |
Sildenafil and N-desmethyl sildenafil | Human Plasma | 0.500–500 ng/mL | K2EDTA |
Stavudine | Human Plasma | 5.00–1,000 ng/mL | K2EDTA |
S-Warfarin | Human Plasma | 10.0–2,500 ng/mL | K2EDTA |
Tacrolimus | Human Whole Blood | 50.0–10,000 pg/mL | K2EDTA |
Tacrolimus | Whole Blood | 0.100–100 ng/mL | K2EDTA |
Tadalafil | Human Plasma | 1.00–500 ng/mL | K3EDTA |
Telmisartan | Human Plasma | 0.500–5,000 ng/mL | K3EDTA |
Temozolomide | Human Plasma | 100–20,000 ng/mL | K2EDTA |
Tenofovir | Human Plasma | 5.00–3,000 ng/mL | K2EDTA |
Tenofovir | Human Plasma | 1.00–500 ng/mL | K2EDTA /K3EDTA |
Threohydrobupropion | Human Plasma | 1.00–1,000 ng/mL | K2EDTA |
Threohydrobupropion | Human Plasma | 1.00–1,000 ng/mL | K2EDTA |
Tiotropium | Human Plasma | 1.00–500 pg/mL | K2EDTA |
Tiotropium | Human Plasma | 0.500–500 pg/mL | K2EDTA |
Tolbutamide / 4-hydroxytolbutamide | Human Plasma | 5.00–5,000 ng/mL | K2EDTA |
Total 4-beta hydroxycholesterol | Human Plasma | 4.00–400 ng/mL | K2EDTA |
Total cholesterol | Human Plasma | 500–5,000 μg/mL | K2EDTA |
Tramadol | Human Plasma | 1.00–500 ng/mL | K2EDTA |
Valproic acid | Human Plasma | 0.200–100 μg/mL | K2EDTA |
Valproic Acid aka valproate | Human Serum | 1–100 μg/mL | NA |
Valsartan | Human Plasma | 50.0–10,000 ng/mL | K2EDTA /K3EDTA |
Vardenafil | Human Plasma | 0.200–50.0 ng/mL | K2EDTA /K3EDTA |
Vincristine | Human Plasma | 0.500–100 ng/mL | K2EDTA |
Voriconazole | Human Plasma | 5.00–5,000 ng/mL | K2EDTA /K3EDTA |
Warfarin (R-) / Warfarin (S-) | Human Plasma | 10.0–1,000 ng/mL | K3EDTA |
Zidovudine | Human Plasma | 4.00–800 ng/mL | K2EDTA |
4-beta Hydroxycholesterol | Human Plasma | 4.00–400 ng/mL | K2EDTA |
Atorvastatin, para-Hydroxy Atorvastatin and ortho-Hydroxy Atorvastatin | Human Plasma | 0.300–50.0 ng/mL | K2EDTA |
Aldosterone | Human Plasma | 10.0–5,000 pg/mL | K2EDTA |
Aldosterone | Human Urine | 0.200–200 ng/mL | K2EDTA |
Bile Acids (11 acids) | Human Plasma | 2.00–1,000 ng/mL/ 1.00–500 ng/mL/ 5.00–2,500 ng/mL | K2EDTA |
Salicylic Acid and Acetylsalicylic Acid | Human Plasma | 25.0–25,000 ng/mL | Sodium Fluoride/Potassium Oxalate |
Thromboxane B2 | Human Serum | 1.00–500 ng/mL | NA |
Total Dabigatran | Human Plasma | 1.10–550 ng/mL | K2EDTA |
Dabigatran | Human Plasma | 1.10–550 ng/mL | K2EDTA |
Irbesartan | Human Plasma | 10.0–10,000 ng/mL | K2EDTA |
Letrozole | Human Plasma | 0.500–250 ng/mL | K2EDTA |